During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

You've learned that you have diffuse large B-cell lymphoma (DLBCL). What happens now? A cancer diagnosis can feel overwhelming. You might not know what to do first. Start by having a conversation ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

New treatment advances are providing a lot of hope, and even a potential cure, for difficult to treat large B-cell lymphoma ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions ...

(A) Schematic of the experimental design and analysis. Paracancerous and cancer tissues obtained from surgically resected DLBCLs were split and processed for scRNA-seq and spatial transcriptomics.

Mr. Zhou, a 63-year-old resident of Shanghai, returned to a hospital for what would become his third fight against diffuse ...